The most frequent ≥ grade 3 adverse events after idelalisib monotherapy in SLL and FL patients include decreased neutrophils (25%), increased ALT (18%), pneumonia (16%), diarrhea (14%), and enchanced AST (12%) [261]; whereas the incidence of ≥ grade 3 adverse events after combination of idelalisib and rituximab in CLL patients comprise neutropenia (34%), thrombocytopenia (10%), anemia (5%), elevation in transaminases (5%), and diarrhea (4%) [262]. This evidence concerns the gene GPT and susceptibility to pneumonia measurement.